Original Article
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
N Engl J Med 2004; 350:896-903February 26, 2004
- Abstract
Background
After the introduction of an inactivated intranasal influenza vaccine that was used only in Switzerland, 46 cases of Bell's palsy were reported.
Methods
We conducted a matched case–control study and a case-series analysis. All primary care physicians, ear, nose, and throat specialists, and neurologists in German-speaking regions of Switzerland were requested to identify cases of Bell's palsy diagnosed in adults between October 1, 2000, and April 30, 2001. Each physician was invited to select three control patients for each patient with Bell's palsy, with matching according to age, date of the clinic visit, and physician. Vaccination information was provided by the physicians.
Results
A total of 773 patients with Bell's palsy were identified. Of the 412 (53.3 percent) who could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control patients; the other 162 patients had no controls. In the case–control study, we found that 68 patients with Bell's palsy (27.2 percent) and 8 controls (1.1 percent) had received the intranasal vaccine (P<0.001). In contrast to parenteral vaccines, the intranasal vaccine significantly increased the risk of Bell's palsy (adjusted odds ratio, 84.0; 95 percent confidence interval, 20.1 to 351.9). Even according to conservative assumptions, the relative risk of Bell's palsy was estimated to be 19 times the risk in the controls, corresponding to 13 excess cases per 10,000 vaccinees within 1 to 91 days after vaccination. In the case-series analysis, the period of highest risk was 31 to 60 days after vaccination.
Conclusions
This study suggests a strong association between the inactivated intranasal influenza vaccine used in Switzerland and Bell's palsy. This vaccine is no longer in clinical use.
Media in This Article
Figure 1
Onset Intervals among the Patients with Bell's Palsy.Table 1
Demographic Characteristics and Underlying Conditions of the Patients with Bell's Palsy and the Controls.Article Activity
- Article
Influenza is a leading cause of illness and death.1 Annual vaccination is recommended for certain age groups and high-risk populations. However, the acceptance of parenteral influenza vaccines has frequently been unsatisfactory, in part because of the fear of injections.2 Intranasal administration of influenza vaccines is an attractive alternative. It might also reduce the transmission of influenza more efficiently than parenteral administration by stimulating both mucosal and systemic immune responses.2,3 To date, two trivalent intranasal influenza vaccines have been developed. An inactivated virosomal-subunit influenza vaccine licensed in Switzerland (Nasalflu, Berna Biotech) was available for the 2000–2001 influenza season; it contained Escherichia coli heat-labile toxin as a mucosal adjuvant. A different live attenuated, cold-adapted influenza vaccine was recently licensed in the United States.4
No serious adverse events were reported with the Swiss vaccine in the prelicensure trials conducted among 1218 volunteers during four winter seasons (1996 to 1999).5-9 It was introduced to the Swiss market in October 2000 as the first licensed intranasal influenza vaccine in the world.
During the seven-month period beginning that month (i.e., October 2000 to April 2001), the Swiss Drug Monitoring Center and various University of Zurich institutions received 46 sentinel case reports of Bell's palsy among recipients of the vaccine, including 43 from German-speaking parts of Switzerland. The media reported these events in March 2001. Subsequently, Berna Biotech suspended distribution of the vaccine and invited our institutions at the University of Zurich to investigate whether the inactivated intranasal vaccine was associated with an increased risk of Bell's palsy. The Centers for Disease Control and Prevention joined the investigation in November 2001. The Swiss intranasal vaccine is now no longer in clinical use.
There has been no systematic survey of Bell's palsy in Switzerland. The reported incidence of Bell's palsy in other countries has ranged from 15 to 40 cases per 100,000 population per year.10-16
Methods
Study Design
We conducted a matched case–control study in which patients with Bell's palsy (case patients) and control patients were matched according to age, date of their clinic visit, and physician. Since about 74,000 doses of the intranasal vaccine, or more than 80 percent of the intranasal-vaccine supply, were distributed in the 19 German-speaking regions of Switzerland, this region was defined as the study area. To gain a better understanding of the timing of the risk for Bell's palsy after administration of the intranasal vaccine, we assessed the onset intervals (i.e., the intervals from the date of the first dose of the vaccine to the date of the first visit to a physician for Bell's palsy) in a larger series of patients, a method referred to as case-series analysis.
The study protocol was approved by the ethics committees of the regions involved in the study. All the patients gave written informed consent, except for a small minority with additional cases reported by physicians anonymously. The academic investigators had access to all the study data, took responsibility for designing and conducting the analysis, and had authority over the manuscript preparation and the decisions concerning publication.
Selection of Case Patients and Controls
All 4891 primary care physicians, ear, nose, and throat specialists, and neurologists in the study area were invited twice to report cases of Bell's palsy first diagnosed between October 1, 2000, and April 30, 2001. The overall response rate was 81.1 percent. Subsequently, the physicians who had reported cases of Bell's palsy were asked to document the date of the visit and information pertinent to the study's inclusion and exclusion criteria and to select, from among their patients without Bell's palsy, three controls sequentially from their registration log. The controls were matched with the case patients according to age (within five years), date of the clinic visit (within four days), and physician. Trained study monitors contacted the physicians and reviewed the selection forms regularly to ensure consistency in the selection of controls. At this point, participating physicians had not been made aware of the exposure to be investigated (influenza vaccination). Thereafter, questionnaires requesting clinical information about the case patients and controls were sent together with informed-consent forms to both the physicians and their patients. The patients' questionnaires were used primarily for validation of the information provided by the physicians. When there was a discrepancy, both the patient and the physician were contacted for clarification.
Patients with Bell's palsy were eligible for the study if they were at least 18 years of age and if they had complete or incomplete unilateral weakness of the facial muscles. The onset of weakness had to be sudden, and the progression of facial palsy had to reach a maximum within one week after the onset of the first symptoms. Exclusion criteria were head trauma within two months before enrollment and a history of brain tumor, cerebrovascular accident, ipsilateral ear disease or surgery, or the Guillain–Barré syndrome. Patients were not selected as controls if they met the same exclusion criteria or if they received a clinical diagnosis of influenza at the index visit. The exclusion of patients with influenza as controls was a measure taken in an effort to prevent an overrepresentation of patients with influenza as controls during the winter season. Physicians who were unwilling to select controls were still asked to document any cases.
Exposure to Influenza Vaccines
Physicians were asked to document the dates of administration and the brand name and type of influenza vaccine (parenteral or intranasal) used during the study period. Other vaccine exposures during the study period and the preceding two months were also documented. Since in all 43 sentinel cases reported in the study area the onset of Bell's palsy occurred within 91 days after intranasal vaccination, we defined the period of 1 to 91 days as the postexposure risk period.
For 10 exposed case patients and 1 exposed control, we were unable to calculate the onset interval because the date of vaccination was unknown. We decided to include them in the conditional logistic-regression analysis on the assumption that they had an onset interval of 1 to 91 days, because including them would provide a more conservative estimate of the adjusted odds ratio for Bell's palsy with use of the intranasal vaccine than would excluding them.
Covariates
Additional information, including potential risk factors for Bell's palsy,11-21 was obtained from physicians and patients. Documented information at the time of enrollment included sex, nationality, pregnancy status, smoking status, current infectious diseases (upper respiratory infections, influenza, herpes simplex, other herpes infections, borreliosis, human immunodeficiency virus infection, and Mycoplasma pneumoniae infection), chronic diseases (diabetes, cardiovascular diseases, hypertension, asthma, allergies, and neoplasm), and a personal or family history of Bell's palsy.
Statistical Analysis
Matched Case–Control Study
The date of the first visit to a physician for Bell's palsy was used as the index date and was documented for all the case patients. The date of administration of the first dose of the intranasal vaccine was defined as the exposure date. Conditional logistic regression (SAS version 8, SAS Institute) was performed to estimate the risk of Bell's palsy during the period from 1 to 91 days after vaccination (the predefined risk period), with adjustment for the potential risk factors defined as covariates.
Case-Series Analysis
To determine which exposure periods after vaccination were associated with the highest risk of Bell's palsy, we performed a case-series analysis.22,23 The case series included 412 case patients (250 from the case–control study and 162 from the group of case patients without controls). We compared the risk of Bell's palsy during various periods after intranasal or parenteral vaccination (1 to 30, 31 to 60, and 61 to 91 days, as compared with 92 or more days).
Risk Assessment after Adjustment for Biases
To assess the presence and the magnitude of selection bias, we compared the number of case patients who had been exposed to the intranasal vaccine during the case–control study with the number of the sentinel case patients and with the series of case patients for whom there were no matched controls. In addition, we estimated the relative and excess risks based on the risk in the adult population and the number of doses of the intranasal vaccine distributed in the study area.
Results
Study Population
A total of 1291 cases of Bell's palsy were reported during the seven-month period in the study area. Eighty-one (6.3 percent) represented duplicate cases, 187 (14.5 percent) involved patients who were not identifiable in the medical records, and 250 (19.4 percent) involved patients who were ineligible for the study because they were younger than 18 years of age (34 patients), had an onset of Bell's palsy before or after the study period (101), did not have Bell's palsy (31), or met one or more exclusion criteria (84).
Of the remaining 773 patients with Bell's palsy, 361 (46.7 percent) were not enrolled because their providers declined to participate; the other 412 (53.3 percent) were enrolled. The diagnosis was confirmed by a specialist in 298 patients (72.3 percent) and by a primary care physician in 114 (27.7 percent). Of the 412 case patients, 250 (60.7 percent) were matched with 722 controls; the providers of the remaining 162 case patients declined to enroll controls.
Case–Control Study
Table 1Table 1
Demographic Characteristics and Underlying Conditions of the Patients with Bell's Palsy and the Controls. summarizes the characteristics of the case patients, controls, and all vaccinees. Sixty-eight of the 250 patients with Bell's palsy (27.2 percent) and 8 of the 722 controls (1.1 percent) had received the inactivated intranasal vaccine (P<0.001). Of the patients who had not received the intranasal vaccine, 27 of the 182 patients with Bell's palsy (14.8 percent) and 90 of the 714 controls (12.6 percent) had been immunized with parenteral influenza vaccine before the index date (Table 2Table 2
Risk of Bell's Palsy among Participants in the Case–Control Study.).Conditional logistic-regression analysis showed that the adjusted odds ratio for a diagnosis of Bell's palsy during the 91-day exposure period among recipients of intranasal vaccine, as compared with controls, was 84.0 (95 percent confidence interval, 20.1 to 351.9) (Table 2). In contrast, there was essentially no risk of Bell's palsy after receipt of the traditional, parenteral influenza vaccine (adjusted odds ratio, 1.1; 95 percent confidence interval, 0.6 to 2.0). The only risk factor for Bell's palsy other than receipt of the intranasal vaccine was a nationality within southern Europe (adjusted odds ratio, 2.4; 95 percent confidence interval, 1.3 to 4.7). In addition, controls were more likely than case patients to have an infectious disease, although the difference was barely significant (adjusted odds ratio, 0.47; 95 percent confidence interval, 0.23 to 0.98).
Case-Series Analysis and Risk Periods
In our case-series analysis of 412 patients, we identified 91 intranasally vaccinated patients with Bell's palsy, 81 of whom had adequate data for calculating onset intervals. Forty-four of these 81 patients (54.3 percent) first visited a physician because of symptoms 31 to 60 days after intranasal vaccination (relative incidence of Bell's palsy after intranasal vaccination, 35.6; 95 percent confidence interval, 14.1 to 89.8), 17 (21.0 percent) had an onset interval of 1 to 30 days (relative incidence, 14.0; 95 percent confidence interval, 5.2 to 37.9), 15 (18.5 percent) had an onset interval of 61 to 91 days (relative incidence, 11.8; 95 percent confidence interval, 4.3 to 32.3), and 5 (6.2 percent) had an onset interval exceeding 91 days (Figure 1Figure 1
Onset Intervals among the Patients with Bell's Palsy.). The onset intervals in sentinel cases had a similar distribution, although in more than one third of the sentinel cases the onset interval was 1 to 30 days. In contrast, 61.5 percent of parenterally vaccinated case patients had an onset interval of more than 91 days. Table 3Table 3
Outcome of Patients with Bell's Palsy. provides data on the neurologic outcome in these patients.Risk Assessment after Adjustment for Biases
We were concerned that in our case–control study we may have overestimated the risk of Bell's palsy after intranasal vaccination, for the following two reasons. First, sentinel cases had a higher probability of being included in the case–control study (22 of 43 cases [51.2 percent]) than nonsentinel cases (228 of 730 [31.2 percent]) (Table 4Table 4
Distribution of Cases of Bell's Palsy According to the Data-Collection Process and Exposure to the Intranasal Vaccine.). Second, the proportion of patients with Bell's palsy who had been exposed to the vaccine was 27.2 percent (68 of 250 patients) in the case–control study but only 14.2 percent (23 of 162 patients) in the series of case patients without controls (Table 4). We used two approaches to estimate the total number of exposed case patients in the entire group of 773 patients with Bell's palsy in order to adjust for this likely overestimation.Approach 1
We assumed that nonsentinel cases of Bell's palsy with vaccine exposure had the same probability of being included in either the case–control study or the case series as did sentinel cases. According to Table 4, this assumption forces the following equation: (22+5)÷43=(46+18)÷(64+x), which is solved when x=38 and which yields an estimate of 145 total (sentinel and nonsentinel) cases with vaccine exposure.
Approach 2
The proportion of cases with vaccine exposure was higher in the case–control study than in the case series, with an odds ratio of 2.25 (27.2 percent vs. 14.2 percent). We assumed that the odds of exposure in the case series was also 2.25 times the odds of exposure in the remaining, unreported cases. This assumption forces the following equation: [0.142÷(1–0.142)]÷[(16+x)÷(361–[16+x])]=2.25, which is solved when x=9 and which yields an estimate of 116 total exposed cases (Table 4).
The more conservative estimate of 116 cases of Bell's palsy with vaccine exposure, as calculated with the second approach, yields an overall risk associated with exposure of 15.0 percent (116 of 773 cases overall). Thus, among 250 cases in the case–control study, one would have expected 38 cases with exposure, rather than the observed 68. This suggests that the adjusted odds ratio in the case–control study may have been overestimated by a factor of (0.272÷[1–0.272])÷(0.150÷[1–0.150]), or 2.1. When we accounted for the overestimation, the estimate of the adjusted odds ratio was reduced to 40.0(84.0÷2.1).
We identified 107 cases of Bell's palsy with vaccine exposure from all sources of information (Table 4). We assumed that they constituted all the exposed cases (and that there were no additional instances of exposure among the 361 nonparticipating patients with Bell's palsy). We also had information on the size of the adult population in the study area (4.056 million) and on the doses of intranasal vaccine that were distributed for 74,000 vaccinees. The estimated 666 cases of Bell's palsy without exposure (773 cases overall, minus 107 cases with exposure) over a seven-month period in a population of 3.982 million adults (4.056 million overall, minus 0.074 million vaccinees) yields a rate of 29 cases per 100,000 population per year.
On the basis of the available onset intervals among the cases of Bell's palsy with vaccine exposure, we estimated that in 93.8 percent of these cases the palsy developed 1 to 91 days after vaccination. Combining this result with the minimum number of 107 for all cases of Bell's palsy with exposure would yield 100 as the number of intranasally vaccinated patients in whom the palsy developed within 1 to 91 days. This would yield an estimated rate of 541 cases of Bell's palsy per 100,000 vaccinees per year, with a relative risk of 19 for the three months after intranasal vaccination and a corresponding excess risk of 13 cases per 10,000 vaccinees.
Discussion
We found that the intranasal influenza vaccine used in Switzerland during the 2000–2001 influenza season greatly increased the risk of Bell's palsy among vaccinees. The association was strong, temporal, and specific. The risk was highest during the second month after intranasal vaccination. In contrast, no significant risk of Bell's palsy was found to be associated with the parenteral influenza vaccines.
We faced substantial challenges in the process of collecting data. Because of strict medical-privacy standards in Switzerland, few physicians would allow us to review the medical records on site or off site, in the form of photocopies. The time required for physicians to enroll both cases and controls became a formidable burden. Consequently, we were able to enroll only about one third of the identified cases in the case–control study. Our data suggested that patients with Bell's palsy who had received the intranasal vaccine were overrepresented in the case–control study, probably because of the regional media coverage of this problem. Furthermore, the exact magnitude of the risk associated with use of the intranasal vaccine was difficult to quantify because of the small number of controls who had received it.
All these factors raised concern about the ability of the case–control study to provide unbiased results. However, even after we adjusted for possible biases, our risk assessment provided strong evidence supporting our findings. Even with the most conservative assumption — that the 107 documented cases with exposure were the only such cases — the association of Bell's palsy and intranasal vaccination was still overwhelming, with a relative risk of at least 19 and an excess risk of 13 cases per 10,000 vaccinees. The population-based risk estimate for the cases of Bell's palsy without exposure was within the ranges reported in the literature.10-16 The relatively high risk of Bell's palsy among southern Europeans has been reported previously.24,25 We cannot explain the finding that controls were more likely than case patients to have infectious diseases, since this variable included multiple diseases, each of which affected only a small number of patients.
The clinical features of the Bell's palsy affecting the patients in this study were consistent with those described in the literature.21 About one in five patients in all the groups had an incomplete recovery; loss to follow-up was more common among parenterally vaccinated or unvaccinated patients than among intranasally vaccinated patients.
The causes and pathogenesis of Bell's palsy remain unclear. Herpes simplex has been suspected,26-28 but autoimmune processes have also been considered.21 The results of studies in animals have raised concern that the adjuvant Escherichia coli heat-labile toxin may be an inflammatory mediator,3,29 but preclinical research on its toxicologic characteristics and biologic distribution did not support this idea,30 and neurologic toxicity of this substance in humans has never been described. Further studies are needed to investigate the pathogenesis of Bell's palsy after use of the inactivated intranasal influenza vaccine. Adverse neurologic events, such as Bell's palsy, should be monitored for at least 60 days when any intranasal influenza vaccine is tested.
In the prelicensure trials of the intranasal influenza vaccine, no cases of Bell's palsy were reported among 1218 recipients (Spyr C, Berna Biotech: personal communication). However, 46 cases of Bell's palsy were reported shortly after licensure. Historically, the sample sizes for even the largest phase 3 trials before licensure have been based on efficacy, not on safety considerations. Unfortunately, as with the experience with the rotavirus vaccine and intussusception,31 the risk of Bell's palsy found after licensure of the intranasal influenza vaccine could not have been detected beforehand, given the sample size in the prelicensure trials. These experiences may reinforce the arguments both for larger prelicensure safety trials32 and for enhanced postlicensure surveillance.33
Dr. Steffen reports having received consultation or lecture fees from Aventis, Berna Biotech, GlaxoSmithKline, Novartis, Powderject, Salix, and SBL Vaccine and grant support from Salix and Berna Biotech.
We are indebted to all the participating physicians and their patients for their cooperation; to Five Office for technical support and field work; to the Collaborative Study Committee (Katharina Hartmann, M.Sc., Joerg Hasford, M.D., Max Kuhn, M.D., Arthur Marx, M.D., Christoph Minder, Ph.D., and Ansgar Studer, M.D.), for advice on the study protocol; to Lorenz Amsler, M.D., for preceding investigations of sentinel cases; to the Swiss Drug Monitoring Center for data on the sentinel cases; and to Berna Biotech for its sponsorship of the study.
Source Information
From the Division of Communicable Diseases, World Health Organization Collaborating Centre for Travellers' Health (M.M., R.S.), and the Cluster for Vital Statistics and Geography of Health (M.B.), Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland; the Epidemic Intelligence Service, Epidemiology Program Office, and the Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta (W.Z., P.R., R.T.C.); the Department of Otorhinolaryngology and Head and Neck Surgery, Kantonsspital Lucerne, Lucerne, Switzerland (T.L.); and Berna Biotech, Berne, Switzerland (C.S.).
Address reprint requests to Dr. Mutsch at the Institute of Social and Preventive Medicine, Sumatra-str. 30, CH-8006 Zurich, Switzerland, or at muetsch@ifspm.unizh.ch.
- References
References
1
Anderson RN. Deaths: leading causes for 2000. National vital statistics reports. Vol. 50. No. 16. Hyattsville, Md.: National Center for Health Statistics, 2002:1-85. (DHHS publication no. (PHS) 2002-1120 PRS 02-0522.)
2
Davis SS . Nasal vaccines. Adv Drug Deliv Rev 2001;51:21-42
CrossRef | Web of Science | Medline3
McNeela EA ,Mills KHG . Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev 2001;51:43-54
CrossRef | Web of Science | Medline4
Belshe RB ,Mendelman PM ,Treanor J , et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-1412
Full Text | Web of Science | Medline5
Gluck U ,Gebbers JO ,Gluck R . Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 1999;73:7780-7786
Web of Science | Medline6
Gluck R ,Mischler R ,Durrer P , et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000;181:1129-1132
CrossRef | Web of Science | Medline7
Glueck R . Review of intranasal influenza vaccine. Adv Drug Deliv Rev 2001;51:203-211
CrossRef | Web of Science | Medline8
Glueck R . Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2002;20:Suppl 1:S42-S44
CrossRef | Web of Science9
de Bernardi di Valserra M ,Zanasi A ,Ragusa S ,Gluck R ,Herzog C . An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin Ther 2002;24:100-111
CrossRef | Web of Science | Medline10
Rowlands S ,Hooper R ,Hughes R ,Burney P . The epidemiology and treatment of Bell's palsy in the UK. Eur J Neurol 2002;9:63-67
CrossRef | Web of Science | Medline11
Brandenburg NA ,Annegers JF . Incidence and risk factors for Bell's palsy in Laredo, Texas: 1974-1982. Neuroepidemiology 1993;12:313-325
CrossRef | Web of Science | Medline12
Marson AG ,Salinas R . Bell's palsy. West J Med 2000;173:266-268
CrossRef | Medline13
De Diego JI ,Primo MP ,Madero R ,Gavilan J . Seasonal patterns of idiopathic facial paralysis: a 16-year study. Otolaryngol Head Neck Surg 1999;120:269-271
CrossRef | Web of Science | Medline14
Tovi F ,Hadar T ,Sidi J ,Sarov I ,Sarov B . Epidemiological aspects of idiopathic peripheral facial palsy. Eur J Epidemiol 1986;2:228-232
CrossRef | Medline15
Katusic SK ,Beard CM ,Weiderholt WC ,Bergstrath EJ ,Kurland LT . Incidence, clinical features, and prognosis in Bell's palsy, Rochester, Minnesota, 1968-1982. Ann Neurol 1986;20:622-627
CrossRef | Web of Science | Medline16
Yanagihara N . Incidence of Bell's palsy. Ann Otol Rhinol Laryngol Suppl 1988;137:3-4
Medline17
Paolino E ,Granieri E ,Tola M ,Panarelli MA ,Carreras M . Predisposing factors in Bell's palsy: a case-control study. J Neurol 1985;232:363-365
CrossRef | Web of Science | Medline18
Papaevangelou V ,Falaina V ,Syriopoulou V ,Theodordou M . Bell's palsy associated with Mycoplasma pneumoniae infection. Pediatr Infect Dis J 1999;18:1024-1026
CrossRef | Web of Science | Medline19
Yanagihara N ,Mori H ,Kozawa T ,Nakamura K ,Kita M . Bell's palsy: nonrecurrent v recurrent and unilateral v bilateral. Arch Otolaryngol 1984;110:374-377
Web of Science | Medline20
Peitersen E . Natural history of Bell's palsy. Acta Otolaryngol Suppl 1992;492:122-124
CrossRef | Medline21
Schaitkin BM, May M, Podvinec M, Ulrich J, Peitersen E, Klein SR. Idiopathic (Bell's) palsy, herpes zoster cephalicus, and other facial nerve disorders of viral origin. In: May M, Schaitkin BM, eds. The facial nerve: May's second edition. New York: Thieme Medical, 2000:319-38.
22
Farrington CP . Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995;51:228-235
CrossRef | Web of Science | Medline23
Farrington CP ,Nash J ,Miller E . Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143:1165-1173[Erratum, Am J Epidemiol 1998;147:93.]
Web of Science | Medline24
Savettieri G ,Salemi G ,Rocca WA , et al. Incidence and lifetime prevalence of Bell's palsy in two Sicilian municipalities. Acta Neurol Scand 1996;94:71-75
CrossRef | Web of Science | Medline25
Goncalves-Coelho TD ,Pinheiro CN ,Ferraz EV ,Alonso-Nieto JL . Clusters of Bell's palsy. Arq Neuropsiquiatr 1997;55:722-727
CrossRef | Web of Science | Medline26
Murakami S ,Mizobuchi M ,Nakashiro Y ,Doi T ,Hato N ,Yanagihara N . Bell's palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996;124:27-30
Web of Science | Medline27
Adour KK ,Ruboyianes JM ,Von Doersten PG , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996;105:371-378
Web of Science | Medline28
Linder TE ,Bodmer D ,Sartoretti S ,Felix H ,Bossart W . Bell's palsy: still a mystery? Otol Neurol 2002;23:Suppl:S15-S15 abstract.
CrossRef29
Fujihashi K ,Koga T ,van Ginkel FW ,Hagiwara Y ,McGhee JR . A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002;20:2431-2438
CrossRef | Web of Science | Medline30
Zurbriggen R ,Metcalfe IC ,Gluck R ,Viret JF ,Moser C . Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines 2003;2:295-304
CrossRef | Medline31
Kramarz P ,France EK ,Destefano F , et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;20:410-416
CrossRef | Web of Science | Medline32
Ellenberg SS . Safety consideration for new vaccine development. Pharmacoepidemiol Drug Saf 2001;10:411-415
CrossRef | Web of Science | Medline33
Jacobson RM ,Adegbenro A ,Pankratz VS ,Poland GA . Adverse events and vaccination -- the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001;19:2428-2433
CrossRef | Web of Science | Medline
- Citing Articles (173)
Citing Articles
1
Wan-Ting Huang, Wei-I Huang, Yu-Wen Huang, Chien-Wen Hsu, Jen-Hsiang Chuang. (2012) The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: A capture–recapture analysis. Vaccine
CrossRef2
Jean-Pierre Amorij, Gideon F.A. Kersten, Vinay Saluja, Wouter F. Tonnis, Wouter L.J. Hinrichs, Bram Slütter, Suzanne M. Bal, Joke A. Bouwstra, Anke Huckriede, Wim Jiskoot. (2012) Towards tailored vaccine delivery: needs, challenges and perspectives. Journal of Controlled Release
CrossRef3
S. Jun, B. Clapp, D. Zlotkowska, T. Hoyt, K. Holderness, M. Maddaloni, D. W. Pascual. (2011) Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. International Immunology
CrossRef4
Y. G. WELDESELASSIE, H. J. WHITAKER, C. P. FARRINGTON. (2011) Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiology and Infection 139:12, 1805-1817
CrossRef5
Satoshi Yuzawa, Tomoko Kurita-Ochiai, Tomomi Hashizume, Ryoki Kobayashi, Yoshimitsu Abiko, Masafumi Yamamoto. (2011) Sublingual vaccination with fusion protein consisting of the functional domain of hemagglutinin A of Porphyromonas gingivalis and Escherichia coli maltose-binding protein elicits protective immunity in the oral cavity. FEMS Immunology & Medical Microbiologyn/a-n/a
CrossRef6
Vincent Pavot, Nicolas Rochereau, Christian Genin, Bernard Verrier, Stéphane Paul. (2011) New insights in mucosal vaccine development. Vaccine
CrossRef7
L.R. Stanberry, J.K. Simon, C. Johnson, P.L. Robinson, J. Morry, M.R. Flack, S. Gracon, A. Myc, T. Hamouda, J.R. Baker. (2011) Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine
CrossRef8
J.F.S. Mann, D. Stieh, K. Klein, D.S. Miranda de Stegmann, M.P. Cranage, R.J. Shattock, P.F. McKay. (2011) Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. Journal of Controlled Release
CrossRef9
Roy Curtiss. (2011) Vaccine Design: Innovative Approaches and Novel Strategies. Expert Review of Vaccines 10:10, 1385-1387
CrossRef10
Leonoor Wijnans, Sandra de Bie, Jeanne Dieleman, Jan Bonhoeffer, Miriam Sturkenboom. (2011) Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine 29:43, 7559-7571
CrossRef11
Seol Hee Hong, Young-Ho Byun, Chung Truong Nguyen, Soo Young Kim, Baik Lin Seong, Songyong Park, Gyu-Jin Woo, Yeup Yoon, Jeong Tae Koh, Kohtaro Fujihashi, Joon Haeng Rhee, Shee Eun Lee. (2011) Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine
CrossRef12
Suzanne M. Bal, Bram Slütter, Rolf Verheul, Joke A. Bouwstra, Wim Jiskoot. (2011) Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. European Journal of Pharmaceutical Sciences
CrossRef13
Grace M. Lee, Sharon K. Greene, Eric S. Weintraub, James Baggs, Martin Kulldorff, Bruce H. Fireman, Roger Baxter, Steven J. Jacobsen, Stephanie Irving, Matthew F. Daley, Ruihua Yin, Allison Naleway, James D. Nordin, Lingling Li, Natalie McCarthy, Claudia Vellozzi, Frank DeStefano, Tracy A. Lieu. (2011) H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project. American Journal of Preventive Medicine 41:2, 121-128
CrossRef14
S. S. Ahmed, S. A. Plotkin, S. Black, R. L. Coffman. (2011) Assessing the Safety of Adjuvanted Vaccines. Science Translational Medicine 3:93, 93rv2-93rv2
CrossRef15
Shailja Tiwari, Sunil Kumar Verma, Govind P. Agrawal, Suresh P. Vyas. (2011) Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. International Journal of Pharmaceutics 413:1-2, 211-219
CrossRef16
Jennifer R. Carmichael, Sukumar Pal, Delia Tifrea, Luis M. de la Maza. (2011) Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine 29:32, 5276-5283
CrossRef17
Dai Mizuno, Takashi Kimoto, Tsunetomo Takei, Akiho Fukuta, Wakako Shinahara, Etsuhisa Takahashi, Mihiro Yano, Hiroshi Kido. (2011) Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. Vaccine 29:33, 5368-5378
CrossRef18
Eder Lilia Romero, Maria Jose Morilla. (2011) Topical and mucosal liposomes for vaccine delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3:4, 356-375
CrossRef19
E Richard Moxon, Claire-Anne Siegrist. (2011) The next decade of vaccines: societal and scientific challenges. The Lancet 378:9788, 348-359
CrossRef20
Alexander Batista-Duharte, Erik B. Lindblad, Ernesto Oviedo-Orta. (2011) Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology Letters 203:2, 97-105
CrossRef21
Louise B Lawson, Elizabeth B Norton, John D Clements. (2011) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Current Opinion in Immunology 23:3, 414-420
CrossRef22
W. Zhao, Z. Zhao, M.W. Russell. (2011) Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins. Molecular Oral Microbiology 26:3, 200-209
CrossRef23
Donatella RM Negri, Zuleika Michelini, Roberta Bona, Maria Blasi, Piero Filati, Pasqualina Leone, Alessandra Rossi, Marina Franco, Andrea Cara. (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opinion on Biological Therapy 11:6, 739-750
CrossRef24
Dubravka Grdic Eliasson, Anja Helgeby, Karin Schön, Caroline Nygren, Karim El-Bakkouri, Walter Fiers, Xavier Saelens, Karin Bengtsson Lövgren, Ida Nyström, Nils Y. Lycke. (2011) A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29:23, 3951-3961
CrossRef25
Nicola Principi, Susanna Esposito, Paola Marchisio. (2011) Present and future of influenza prevention in pediatrics. Expert Opinion on Biological Therapy 11:5, 641-653
CrossRef26
Flavia Ferrantelli, Maria Teresa Maggiorella, Ilaria Schiavoni, Leonardo Sernicola, Erika Olivieri, Stefania Farcomeni, Maria Rosaria Pavone-Cossut, Sonia Moretti, Roberto Belli, Barbara Collacchi, Indresh K. Srivastava, Fausto Titti, Aurelio Cafaro, Susan W. Barnett, Barbara Ensoli. (2011) A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine 29:16, 2918-2932
CrossRef27
Mi-Na Kweon. (2011) Sublingual mucosa: A new vaccination route for systemic and mucosal immunity. Cytokine 54:1, 1-5
CrossRef28
Christian Moser, Mario Amacker, Rinaldo Zurbriggen. (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Review of Vaccines 10:4, 437-446
CrossRef29
Peter F. Wright. (2011) Inductive/Effector Mechanisms for Humoral Immunity at Mucosal Sites. American Journal of Reproductive Immunology 65:3, 248-252
CrossRef30
David Burt, Corey Mallett, Martin Plante, Joseph Zimmermann, Krikor Torossian, Louis Fries. (2011) Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Review of Vaccines 10:3, 365-375
CrossRef31
E.A. McLaughlin, R.J. Aitken. (2011) Is there a role for immunocontraception?. Molecular and Cellular Endocrinology 335:1, 78-88
CrossRef32
Ana Vujanic, Philip Sutton, Kenneth J. Snibson, Hung-Hsun Yen, Jean-Pierre Y. Scheerlinck. (2011) Mucosal vaccination: Lung versus nose. Veterinary Immunology and Immunopathology
CrossRef33
Afton L. Thompson, Herman F. Staats. (2011) Cytokines: The Future of Intranasal Vaccine Adjuvants. Clinical and Developmental Immunology 2011, 1-17
CrossRef34
Diogo Fraxino de Almeida, Adilson Teixeira Teodoro, Rafael de Figueiredo Radaeli. (2011) Transient Oculomotor Palsy after Influenza Vaccination: Short Report. ISRN Neurology 2011, 1-3
CrossRef35
Anne L Bishop, Andrew Camilli. (2011) Vibrio cholerae : lessons for mucosal vaccine design. Expert Review of Vaccines 10:1, 79-94
CrossRef36
Ju-Hyun Kim, Mee-Young Kim, Jeong-Uk Lee, Jeong-A Lee, Na-Mi Yoon, Byong-Yong Hwang, Bokyung Kim, Junghwan Kim. (2011) The Effects of Symmetrical Self-performed Facial Muscle Exercises on the Neuromuscular Facilitation of Patients with Facial Palsy. Journal of Physical Therapy Science 23:4, 543-547
CrossRef37
Juan J. Picazo, Javier de Arístegui Fernández, Jose M. Arteagoitia Axpe, Dolores Barranco Ordóñez, Aurelio Barricarte Gurrea, Xavier Bosch José, Javier Díez Domingo, Fernando González Romo, Teresa Hernández-Sampelayo Matos, Jesús Ruiz Contreras, Lluís Salleras. (2011) Evidencias científicas disponibles sobre la seguridad de las vacunas. Vacunas 12:1, 3-34
CrossRef38
Simon H Bridge, Sally A Sharpe, Mike J Dennis, Stuart D Dowall, Brian Getty, Donald S Anson, Michael A Skinner, James P Stewart, Tom J Blanchard. (2011) Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virology Journal 8:1, 429
CrossRef39
(2011) Nippon Jibiinkoka Gakkai Kaiho 114:11, 843-850
CrossRef40
Shailja Tiwari, Govind P Agrawal, Suresh P Vyas. (2010) Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine 5:10, 1617-1640
CrossRef41
Melanie Cochrane, Charles W Armitage, Connor P O’Meara, Kenneth W Beagley. (2010) Towards a Chlamydia trachomatis vaccine: how close are we?. Future Microbiology 5:12, 1833-1856
CrossRef42
Nils Lycke. (2010) Is the choice of vaccine adjuvant critical for long-term memory development?. Expert Review of Vaccines 9:12, 1357-1361
CrossRef43
Pooja Ralli-Jain, Delia Tifrea, Chunmei Cheng, Sukumar Pal, Luis M. de la Maza. (2010) Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 28:48, 7659-7666
CrossRef44
Zhiwei Sui, Quanjiao Chen, Fang Fang, Mei Zheng, Ze Chen. (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:48, 7690-7698
CrossRef45
N Lycke, M Bemark. (2010) Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunology 3:6, 556-566
CrossRef46
William M. Gwinn, Shaun M. Kirwan, Sheena H. Wang, Kathleen A. Ashcraft, Neil L. Sparks, Catherine R. Doil, Tom G. Tlusty, Leslie S. Casey, Susan K. Hollingshead, David E. Briles, Richard S. Dondero, Anthony J. Hickey, W. Michael Foster, Herman F. Staats. (2010) Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine 28:42, 6901-6914
CrossRef47
Jean-Pierre Amorij, Wouter LJ Hinrichs, Henderik W Frijlink, Jan C Wilschut, Anke Huckriede. (2010) Needle-free influenza vaccination. The Lancet Infectious Diseases 10:10, 699-711
CrossRef48
Takeshi Ichinohe, Akira Ainai, Yasushi Ami, Noriyo Nagata, Naoko Iwata, Akira Kawaguchi, Yuriko Suzaki, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, David R. Strayer, William A. Carter, Joe Chiba, Shin-ichi Tamura, Tetsutaro Sata, Takeshi Kurata, Hideki Hasegawa. (2010) Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. Journal of Medical Virology 82:10, 1754-1761
CrossRef49
Pernilla Petersson, Mona Hedenskog, Denise Alves, Mia Brytting, Ulf Schröder, Annika Linde, Åke Lundkvist. (2010) The Eurocine® L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 28:39, 6491-6497
CrossRef50
Catherine Hervouet, Carmelo Luci, Nicolas Çuburu, Magali Cremel, Selma Bekri, Lene Vimeux, Concepcion Marañon, Cecil Czerkinsky, Anne Hosmalin, Fabienne Anjuère. (2010) Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28:34, 5582-5590
CrossRef51
Matthew Paul, Julian K-C Ma. (2010) Plant-made immunogens and effective delivery strategies. Expert Review of Vaccines 9:8, 821-833
CrossRef52
Shin-ichi Tamura. (2010) Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 28:38, 6393-6397
CrossRef53
Li-Ping Tseng, Hong-Jen Liang, Ming-Chung Deng, Kuo-Ming Lee, Ryh-Nan Pan, Jen-Chang Yang, Yi-You Huang, Der-Zen Liu. (2010) The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease. The Veterinary Journal 185:2, 204-210
CrossRef54
Tom Jefferson, Carlo Di Pietrantonj, Alessandro Rivetti, Ghada A Bawazeer, Lubna A Al-Ansary, Eliana Ferroni, Tom Jefferson. 2010. Vaccines for preventing influenza in healthy adults. .
CrossRef55
Tomonori Nochi, Yoshikazu Yuki, Haruko Takahashi, Shin-ichi Sawada, Mio Mejima, Tomoko Kohda, Norihiro Harada, Il Gyu Kong, Ayuko Sato, Nobuhiro Kataoka, Daisuke Tokuhara, Shiho Kurokawa, Yuko Takahashi, Hideo Tsukada, Shunji Kozaki, Kazunari Akiyoshi, Hiroshi Kiyono. (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nature Materials 9:7, 572-578
CrossRef56
Herman F. Staats, Kam W. Leong. (2010) Polymer hydrogels: Chaperoning vaccines. Nature Materials 9:7, 537-538
CrossRef57
C. Liu, T. Hashizume, T. Kurita-Ochiai, K. Fujihashi, M. Yamamoto. (2010) Oral immunization with Porphyromonas gingivalis outer membrane protein and CpG oligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity. Molecular Oral Microbiology 25:3, 178-189
CrossRef58
Vinay Saluja, Jean P. Amorij, Maarten L. Roosmalen, Kees Leenhouts, Anke Huckriede, Wouter L. J. Hinrichs, Henderik W. Frijlink. (2010) Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant. The AAPS Journal 12:2, 109-116
CrossRef59
Donatella R.M. Negri, Antonella Riccomi, Dora Pinto, Silvia Vendetti, Alessandra Rossi, Rosella Cicconi, Paolo Ruggiero, Giuseppe Del Giudice, Maria Teresa De Magistris. (2010) Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 28:25, 4175-4180
CrossRef60
Ali Azizi, Haitham Ghunaim, Francisco Diaz-Mitoma, Jiri Mestecky. (2010) Mucosal HIV vaccines: A holy grail or a dud?. Vaccine 28:24, 4015-4026
CrossRef61
Neetu Singh, Aseem Pandey, Suresh K. Mittal. (2010) Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Reviews in Molecular Medicine 12,
CrossRef62
Zhiwei Sui, Quanjiao Chen, Rui Wu, Hongbo Zhang, Mei Zheng, Hanzhong Wang, Ze Chen. (2010) Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Archives of Virology 155:4, 535-544
CrossRef63
Megan J. Brooks, Joseph J. Sasadeusz, Gregory A. Tannock. 2010. Brief History of Clinical Trials on Viral Vaccines. .
CrossRef64
Esther Tamayo, Jorge Postigo, Jovanna González, Maigualida Fernández-Rey, Marcos Iglesias, Inés Santiuste, Carlo Riccardi, Rino Rappuoli, Giuseppe Del Giudice, Ramón Merino, Jesús Merino. (2010) GITR contributes to the systemic adjuvanticity of the Escherichia coli heat-labile enterotoxin. European Journal of Immunology 40:3, 754-763
CrossRef65
Ali M. Harandi, Donata Medaglini, Robin J. Shattock. (2010) Vaccine adjuvants: A priority for vaccine research. Vaccine 28:12, 2363-2366
CrossRef66
Thomas E. Linder, Wael Abdelkafy, Sandra Cavero-Vanek. (2010) The Management of Peripheral Facial Nerve Palsy. Otology & Neurotology 31:2, 319-327
CrossRef67
Juliana Bessa, Martin F. Bachmann. (2010) T Cell-dependent and -Independent IgA Responses: Role of TLR Signalling. Immunological Investigations 39:4-5, 407-428
CrossRef68
Takeshi Ichinohe, Akira Ainai, Tomoyuki Nakamura, Yukihito Akiyama, Jun-ichi Maeyama, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, Hirofumi Sawa, Shin-ichi Tamura, Joe Chiba, Takeshi Kurata, Tetsutaro Sata, Hideki Hasegawa. (2010) Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Journal of Medical Virology 82:1, 128-137
CrossRef69
Sun-Young Oh, Ji-Hoon Kang, Chang-Seop Lee. (2010) Bell's Palsy Associated with Scrub Typhus. Infection and Chemotherapy 42:4, 253
CrossRef70
Hiroyuki Kayamuro, Shin-ichi Tsunoda, Yasuo Tsutsumi. (2010) Development of functional cytokines as novel mucosal vaccine adjuvants. Drug Delivery System 25:1, 22-28
CrossRef71
Hiroyuki KAYAMURO, Yasuo YOSHIOKA, Yasuhiro ABE, Haruhiko KAMADA, Shin-ichi TSUNODA, Yasuo TSUTSUMI. (2010) Application of Bioactive Mutant TNF Alpha to a Mucosal Vaccine Adjuvant. YAKUGAKU ZASSHI 130:1, 55-61
CrossRef72
Tom Jefferson, Chris Del Mar, Liz Dooley, Eliana Ferroni, Lubna A Al-Ansary, Ghada A Bawazeer, Mieke L van Driel, Sreekumaran Nair, Ruth Foxlee, Alessandro Rivetti. 2010. .
CrossRef73
Takeshi Tanimoto. (2010) Development of intranasal influenza vaccine. Drug Delivery System 25:1, 15-21
CrossRef74
Ulrich Heininger. (2009) A risk–benefit analysis of vaccination. Vaccine 27, G9-G12
CrossRef75
Tao Zhang, Tomomi Hashizume, Tomoko Kurita-Ochiai, Masafumi Yamamoto. (2009) Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochemical and Biophysical Research Communications 390:3, 937-941
CrossRef76
Silvia Vendetti, Antonella Riccomi, Donatella R.M. Negri, Filippo Veglia, Ester Sciaraffia, Maria Teresa De Magistris. (2009) Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization. Methods 49:4, 334-339
CrossRef77
Danica K. Hickey, Frank E. Aldwell, Zi Yan Tan, Shisan Bao, Kenneth W. Beagley. (2009) Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Vaccine 27:50, 6983-6990
CrossRef78
Lindsay J. Hall, Simon Clare, Derek Pickard, Simon O. Clark, Dominic L.F. Kelly, Moataz Abd El Ghany, Christine Hale, Jes Dietrich, Peter Andersen, Philip D. Marsh, Gordon Dougan. (2009) Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein. Vaccine 27:49, 6894-6904
CrossRef79
Hiroyuki Kayamuro, Yasuhiro Abe, Yasuo Yoshioka, Kazufumi Katayama, Tetsuya Nomura, Tokuyuki Yoshida, Kohei Yamashita, Tomoaki Yoshikawa, Yuichi Kawai, Tadanori Mayumi, Takachika Hiroi, Norio Itoh, Kazuya Nagano, Haruhiko Kamada, Shin-ichi Tsunoda, Yasuo Tsutsumi. (2009) The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 30:29, 5869-5876
CrossRef80
Danica K. Hickey, Frank E. Aldwell, Kenneth W. Beagley. (2009) Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Vaccine 27:44, 6217-6225
CrossRef81
Kosuke Kataoka, Kohtaro Fujihashi. (2009) Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Review of Vaccines 8:9, 1183-1193
CrossRef82
Maki Nishino, Dai Mizuno, Takashi Kimoto, Wakako Shinahara, Akiho Fukuta, Tsunetomo Takei, Kaori Sumida, Seiichiro Kitamura, Hiroshi Shiota, Hiroshi Kido. (2009) Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine 27:41, 5620-5627
CrossRef83
Joan Puig-Barberà. (2009) MF59 ® -adjuvanted seasonalinfluenza vaccine. Aging Health 5:4, 475-481
CrossRef84
Yoshikazu Yuki, Hiroshi Kiyono. (2009) Mucosal vaccines: novel advances in technology and delivery. Expert Review of Vaccines 8:8, 1083-1097
CrossRef85
Kelly A. Cunningham, Alison J. Carey, Nils Lycke, Peter Timms, Kenneth W. Beagley. (2009) CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. Journal of Reproductive Immunology 81:1, 34-38
CrossRef86
Naoto Yoshino, Kohtaro Fujihashi, Yukari Hagiwara, Hiroyuki Kanno, Kiyomi Takahashi, Ryoki Kobayashi, Noriyuki Inaba, Masatoshi Noda, Shigehiro Sato. (2009) Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 27:35, 4808-4817
CrossRef87
Hiroyuki Kayamuro, Yasuo Yoshioka, Yasuhiro Abe, Kazufumi Katayama, Tokuyuki Yoshida, Kohei Yamashita, Tomoaki Yoshikawa, Takachika Hiroi, Norio Itoh, Yuichi Kawai, Tadanori Mayumi, Haruhiko Kamada, Shin-ichi Tsunoda, Yasuo Tsutsumi. (2009) TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochemical and Biophysical Research Communications 384:3, 296-300
CrossRef88
Brigitte Autran, Edwin J Asturias, Stephen Evans, Kenneth Hartigan-Go, Gregory Hussey, T Jacob John, Paul-Henri Lambert, Barbara Law, Karen Midthun, Hanna Nohynek, Stefania Salmaso, Peter G Smith, Patrick LF Zuber, Adwoa Bentsi-Enchill, Aleksandra Caric, Dina Pfeifer, Philippe Duclos, David Wood. (2009) Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Review of Vaccines 8:6, 705-716
CrossRef89
Arnold S Monto, Suzanne E Ohmit. (2009) Seasonal influenza vaccines: evolutions and future trends. Expert Review of Vaccines 8:4, 383-389
CrossRef90
Yuri Ghendon, Stanislav Markushin, Yuri Vasiliev, Irina Akopova, Irina Koptiaeva, Georgy Krivtsov, Olga Borisova, Nelly Ahmatova, Ekaterina Kurbatova, Svetlana Mazurina, Valentina Gervazieva. (2009) Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. Journal of Medical Virology 81:3, 494-506
CrossRef91
Ali M Harandi, Gwyn Davies, Ole F Olesen. (2009) Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines 8:3, 293-298
CrossRef92
Sameer Sharma, T.K.S. Mukkur, Heather A.E. Benson, Yan Chen. (2009) Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Journal of Pharmaceutical Sciences 98:3, 812-843
CrossRef93
Jun-ichi Maeyama, Takako Komiya, Motohide Takahashi, Masanori Isaka, Norihisa Goto, Saburo Yamamoto. (2009) The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid. Vaccine 27:8, 1166-1173
CrossRef94
Martin P Cranage, Maria Manoussaka. (2009) Modern Mucosal Vaccines, Adjuvants and Microbicides. Expert Review of Anti-infective Therapy 7:1, 21-23
CrossRef95
Edgar Badell, Fabienne Nicolle, Simon Clark, Laleh Majlessi, Frédéric Boudou, Angelo Martino, Luiz Castello-Branco, Claude Leclerc, David J.M. Lewis, Philip D. Marsh, Brigitte Gicquel, Nathalie Winter. (2009) Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells. Vaccine 27:1, 28-37
CrossRef96
Emiliano Tesoro Cruz, Iris Angélica Feria Romero, Juan Gabriel López Mendoza, Sandra Orozco Suárez, Rafael Hernández González, Francisco Blanco Favela, Armando Pérez Torres, José Álvaro Aguilar Setién. (2008) Efficient post-exposure prophylaxis against rabies by applying a four-dose DNA vaccine intranasally. Vaccine 26:52, 6936-6944
CrossRef97
C. Sundling, K. Schon, A. Morner, M. N. E. Forsell, R. T. Wyatt, R. Thorstensson, G. B. K. Hedestam, N. Y. Lycke. (2008) CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. Journal of General Virology 89:12, 2954-2964
CrossRef98
Bram Palache. (2008) New vaccine approaches for seasonal and pandemic influenza. Vaccine 26:49, 6232-6236
CrossRef99
John A Mikszta, Philippe E Laurent. (2008) Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Review of Vaccines 7:9, 1329-1339
CrossRef100
Don Gilden. (2008) Treatment of Bell's palsy—the pendulum has swung back to steroids alone. The Lancet Neurology 7:11, 976-977
CrossRef101
Takeshi Ichinohe, Akiko Iwasaki, Hideki Hasegawa. (2008) Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Review of Vaccines 7:9, 1435-1445
CrossRef102
Ulrich Baumann. (2008) Mucosal vaccination against bacterial respiratory infections. Expert Review of Vaccines 7:8, 1257-1276
CrossRef103
Jorma Hinkula, Marie Hagbom, Britta Wahren, Ulf Schroder. (2008) Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice. Vaccine 26:40, 5101-5106
CrossRef104
Paul Henri Lambert, Philippe E. Laurent. (2008) Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?. Vaccine 26:26, 3197-3208
CrossRef105
H Kamijuku, Y Nagata, X Jiang, T Ichinohe, T Tashiro, K Mori, M Taniguchi, K Hase, H Ohno, T Shimaoka, S Yonehara, T Odagiri, M Tashiro, T Sata, H Hasegawa, K-i Seino. (2008) Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunology 1:3, 208-218
CrossRef106
Y. Ghendon, S. Markushin, G. Krivtsov, I. Akopova. (2008) Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Archives of Virology 153:5, 831-837
CrossRef107
Emiliano Tesoro-Cruz, Rafael Calderón-Rodríguez, Rafael Hernández-González, Francisco Blanco-Favéla, Alvaro Aguilar-Setién. (2008) Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus. Veterinary Research 39:2, 16
CrossRef108
J.-H. Song, H. H. Nguyen, N. Cuburu, T. Horimoto, S.-Y. Ko, S.-H. Park, C. Czerkinsky, M.-N. Kweon. (2008) From the Cover: Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proceedings of the National Academy of Sciences 105:5, 1644-1649
CrossRef109
Dubravka Grdic Eliasson, Karim El Bakkouri, Karin Schön, Anna Ramne, Els Festjens, Björn Löwenadler, Walter Fiers, Xavier Saelens, Nils Lycke. (2008) CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26:9, 1243-1252
CrossRef110
Anna U. Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, David M. Markovitz, David C. Montefiori, James R. Baker. (2008) Nasal Immunization with a Recombinant HIV gp120 and Nanoemulsion Adjuvant Produces Th1 Polarized Responses and Neutralizing Antibodies to Primary HIV Type 1 Isolates. AIDS Research and Human Retroviruses 24:2, 271-281
CrossRef111
John Iskander, Karen Broder. (2008) Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. Expert Review of Vaccines 7:1, 75-82
CrossRef112
Li Guo, Jianwei Wang, Hongli Zhou, Hongli Si, Min Wang, Jingdong Song, Bingjuan Han, Yi Shu, Lili Ren, Jianguo Qu, Tao Hung. (2008) Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine 26:4, 460-468
CrossRef113
YUICHI KURONO. (2008) Nippon Jibiinkoka Gakkai Kaiho 111:11, 689-694
CrossRef114
Kai Schulze, Oliver Goldmann, Eva Medina, Carlos A. Guzmán. (2008) The FAI protein of group C streptococci acts as a mucosal adjuvant by the specific targeting and activation of B cells. International Journal of Medical Microbiology 298:1-2, 3-10
CrossRef115
Nicolas Çuburu, Mi-Na Kweon, Joo-Hye Song, Catherine Hervouet, Carmelo Luci, Jia-Bin Sun, Paul Hofman, Jan Holmgren, Fabienne Anjuère, Cecil Czerkinsky. (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25:51, 8598-8610
CrossRef116
Gilden, Donald H., Tyler, Kenneth L., . (2007) Bell's Palsy — Is Glucocorticoid Treatment Enough?. New England Journal of Medicine 357:16, 1653-1655
Full Text117
Christian Moser, Mario Amacker, Andreas R Kammer, Silvia Rasi, Nicole Westerfeld, Rinaldo Zurbriggen. (2007) Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Review of Vaccines 6:5, 711-721
CrossRef118
Terry D Connell. (2007) Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins. Expert Review of Vaccines 6:5, 821-834
CrossRef119
Gregory M Glenn, David C Flyer, Larry R Ellingsworth, Sarah A Frech, David M Frerichs, Robert C Seid, Jianmei Yu. (2007) Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Review of Vaccines 6:5, 809-819
CrossRef120
Gideon Kersten, Hoang Hirschberg. (2007) Needle-free vaccine delivery. Expert Opinion on Drug Delivery 4:5, 459-474
CrossRef121
Takeshi Ichinohe, Akira Kawaguchi, Shin-ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Joe Chiba, Tetsutaro Sata, Takeshi Kurata, Hideki Hasegawa. (2007) Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes and Infection 9:11, 1333-1340
CrossRef122
Per Brandtzaeg. (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:30, 5467-5484
CrossRef123
Jan Bonhoeffer, Ulrich Heininger. (2007) Adverse events following immunization: perception and evidence. Current Opinion in Infectious Diseases 20:3, 237-246
CrossRef124
Vittorio Demicheli, Carlo Di Pietrantonj, Tom Jefferson, Alessandro Rivetti, Daniela Rivetti, Daniela Rivetti. 2007. Vaccines for preventing influenza in healthy adults. .
CrossRef125
Dongmei Lu, Anthony J Hickey. (2007) Pulmonary vaccine delivery. Expert Review of Vaccines 6:2, 213-226
CrossRef126
Cheng-Hsiu Chou, Wen-Ping Liou, Kun-I Hu, Ching-Hui Loh, Chih-Chieh Chou, Yeong-Hwang Chen. (2007) Bell's palsy associated with influenza vaccination: Two case reports. Vaccine 25:15, 2839-2841
CrossRef127
Hideki Hasegawa, Takeshi Ichinohe, Shin-ichi Tamura, Takeshi Kurata. (2007) Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Review of Vaccines 6:2, 193-201
CrossRef128
Mónica Olivares, Maria Paz Díaz-Ropero, Saleta Sierra, Federico Lara-Villoslada, Juristo Fonollá, Mónica Navas, Juan Miguel Rodríguez, Jordi Xaus. (2007) Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition 23:3, 254-260
CrossRef129
Evelien Zonneveld-Huijssoon, Arash Ronaghy, Marion A. J. Van Rossum, Ger T. Rijkers, Fiona R. M. Van Der Klis, Elisabeth A. M. Sanders, Patricia E. Vermeer-De Bondt, Arno W. Hoes, Jan Jaap Van Der Net, Carla Engels, Wietse Kuis, Berent J. Prakken, Maarten J. D. Van Tol, Nico M. Wulffraat. (2007) Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis & Rheumatism 56:2, 639-646
CrossRef130
Jacqueline L. Deen, John D. Clemens. (2006) Issues in the design and implementation of vaccine trials in less developed countries. Nature Reviews Drug Discovery 5:11, 932-940
CrossRef131
Hansi J Dean. (2006) Alternative routes of influenza vaccine delivery. Expert Opinion on Drug Delivery 3:5, 557-561
CrossRef132
Xia C Thai, Lou Ann Bruno-Murtha. (2006) Bell's Palsy Associated with Linezolid Therapy: Case Report and Review of Neuropathic Adverse Events. Pharmacotherapy 26:8, 1183-1189
CrossRef133
Kai Schulze, Colleen Olive, Thomas Ebensen, Carlos A. Guzmán. (2006) Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine 24:35-36, 6088-6095
CrossRef134
Takeshi Ichinohe, Izumi Watanabe, Eriko Tao, Satoshi Ito, Akira Kawaguchi, Shin-ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Masami Moriyama, Joe Chiba, Katsuhiro Komase, Yujiro Suzuki, Takeshi Kurata, Tetsutaro Sata, Hideki Hasegawa. (2006) Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. Journal of Medical Virology 78:7, 954-963
CrossRef135
Patrick Couvreur, Christine Vauthier. (2006) Nanotechnology: Intelligent Design to Treat Complex Disease. Pharmaceutical Research 23:7, 1417-1450
CrossRef136
Heather J. Whitaker, C. Paddy Farrington, Bart Spiessens, Patrick Musonda. (2006) Tutorial in biostatistics: the self-controlled case series method. Statistics in Medicine 25:10, 1768-1797
CrossRef137
Aviva Joseph, Noga Itskovitz-Cooper, Sarit Samira, Orli Flasterstein, Hagit Eliyahu, Dmitri Simberg, Itzik Goldwaser, Yechezkel Barenholz, Eli Kedar. (2006) A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS). Vaccine 24:18, 3990-4006
CrossRef138
Jean-Pierre Y. Scheerlinck, Susie Gekas, Hung-Hsun Yen, Stirling Edwards, Martin Pearse, Alan Coulter, Phil Sutton. (2006) Local immune responses following nasal delivery of an adjuvanted influenza vaccine. Vaccine 24:18, 3929-3936
CrossRef139
Brian R. Sloat, Zhengrong Cui. (2006) Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. Journal of Pharmacy and Pharmacology 58:4, 439-447
CrossRef140
Stanley S. Davis. (2006) The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24, S7-S10
CrossRef141
Alejandro D. Montaner, Analía De Nichilo, Fernanda Elias, Juan M. Rodríguez, Juan M. Fló, Ricardo A. López, Jorge Zorzopulos, Ronald Frank. (2006) Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route. Vaccine 24:11, 1889-1896
CrossRef142
H. Bakke, H. H. Samdal, J. Holst, F. Oftung, I. L. Haugen, A.-C. Kristoffersen, A. Haugan, L. Janakova, G. E. Korsvold, G. Krogh, E. A. S. Andersen, P. Djupesland, T. Holand, R. Rappuoli, B. Haneberg. (2006) Oral Spray Immunization May Be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies but not Nasal Mucosal or Cellular Immunity. Scandinavian Journal of Immunology 63:3, 223-231
CrossRef143
Michael Vajdy, Manmohan Singh. (2006) Intranasal delivery of vaccines against HIV. Expert Opinion on Drug Delivery 3:2, 247-259
CrossRef144
Thomas A Russo, James R Johnson. (2006) Extraintestinal isolates of Escherichia coli : identification and prospects for vaccine development. Expert Review of Vaccines 5:1, 45-54
CrossRef145
A. A. Akhiani, A. Stensson, K. Schon, N. Lycke. (2006) The Nontoxic CTA1-DD Adjuvant Enhances Protective Immunity Against Helicobacter pylori Infection Following Mucosal Immunization. Scandinavian Journal of Immunology 63:2, 97-105
CrossRef146
Marian R. Neutra, Pamela A. Kozlowski. (2006) Mucosal vaccines: the promise and the challenge. Nature Reviews Immunology 6:2, 148-158
CrossRef147
Marina De Filette, Anna Ramne, Ashley Birkett, Nils Lycke, Björn Löwenadler, Willy Min Jou, Xavier Saelens, Walter Fiers. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:5, 544-551
CrossRef148
John Treanor, Carrie Nolan, Diane O’Brien, David Burt, George Lowell, Janine Linden, Louis Fries. (2006) Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24:3, 254-262
CrossRef149
Gretel Sardiñas, Karen Reddin, Rolando Pajon, Andrew Gorringe. (2006) Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine 24:2, 206-214
CrossRef150
Samir Mitragotri. (2005) Immunization without needles. Nature Reviews Immunology 5:12, 905-916
CrossRef151
Herman Bueving, Johannes Wouden. (2005) Helpt influenzavaccinatie bij kinderen met astma?. Huisarts en Wetenschap 48:13, 36-40
CrossRef152
Marcel Maier, Timothy J. Seabrook, Cynthia A. Lemere. (2005) Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23:44, 5149-5159
CrossRef153
Anke Huckriede, Laura Bungener, Toon Stegmann, Toos Daemen, Jeroen Medema, Abraham M. Palache, Jan Wilschut. (2005) The virosome concept for influenza vaccines. Vaccine 23, S26-S38
CrossRef154
G. Bizanov, L. Janakova, S.-E. Knapstad, T. Karlstad, H. Bakke, I. L. Haugen, A. Haugan, H. H. Samdal, B. Haneberg. (2005) Immunoglobulin-A antibodies in Upper Airway Secretions may Inhibit Intranasal Influenza Virus Replication in Mice but not Protect Against Clinical Illness. Scandinavian Journal of Immunology 61:6, 503-510
CrossRef155
Ami Schattner. (2005) Consequence or coincidence?. Vaccine 23:30, 3876-3886
CrossRef156
Jiri Mestecky, Zina Moldoveanu, Michael W. Russell. (2005) Immunologic Uniqueness of the Genital Tract: Challenge for Vaccine Development. American Journal of Reproductive Immunology 53:5, 208-214
CrossRef157
Nils Lycke. (2005) From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunology Letters 97:2, 193-198
CrossRef158
(2005) Australian Society for Geriatric Medicine Position Statement No. 7 Immunisation of Older People Revised 2004. Australasian Journal on Ageing 24:1, 47-52
CrossRef159
Satomi Maeba, Shigeo Otake, Jun Namikoshi, Yasuko Shibata, Mitsuo Hayakawa, Yoshimitsu Abiko, Masafumi Yamamoto. (2005) Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis. Vaccine 23:19, 2513-2521
CrossRef160
Matthew Hoare, Tracy Woodall, Graeme J.M. Alexander. (2005) Case Report: Bell's Palsy Associated with IFN-α and Ribavirin Therapy for Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 25:3, 174-176
CrossRef161
Thomas Linder, Walter Bossart, Daniel Bodmer. (2005) Bell's Palsy and Herpes Simplex Virus: Fact or Mystery?. Otology & Neurotology 26:1, 109-113
CrossRef162
Alexandra Duverger, Ryoki Kobayashi, Tatsuya Fukuiwa, Keiko Fujihashi, Daniel Tome, Kohtaro Fujihashi, Jerry R. McGhee, Prosper N. Boyaka. (2005) Non-GMI Ganglioside-Targeting Bacterial Toxins and Derivatives with Mucosal Adjuvant Activity. International Journal of Oral-Medical Sciences 4:2, 53-60
CrossRef163
NILS LYCKE. (2004) ADP-Ribosylating Bacterial Enzymes for the Targeted Control of Mucosal Tolerance and Immunity. Annals of the New York Academy of Sciences 1029:1, 193-208
CrossRef164
William R. Jarvis. (2004) The State of the Science of health care epidemiology, infection control, and patient safety, 2004. American Journal of Infection Control 32:8, 496-503
CrossRef165
Benjamin J. Song, Rohit K. Katial. (2004) Update on side effects from common vaccines. Current Allergy and Asthma Reports 4:6, 447-453
CrossRef166
Derek T. O'Hagan, Rino Rappuoli. (2004) The safety of vaccines. Drug Discovery Today 9:19, 846-854
CrossRef167
David B. Huang, Jashin J. Wu, Stephen K. Tyring. (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. Journal of Infection 49:3, 179-209
CrossRef168
Gilden, Donald H., . (2004) Bell's Palsy. New England Journal of Medicine 351:13, 1323-1331
Full Text169
B. Genton, V. D'Acremont. (2004) Intranasal versus Injectable Influenza Vaccine. Clinical Infectious Diseases 39:5, 754-754
CrossRef170
Hiroshi Kiyono, Satoshi Fukuyama. (2004) Nalt- versus peyer's-patch-mediated mucosal immunity. Nature Reviews Immunology 4:9, 699-710
CrossRef171
Gideon Kersten, Hoang Hirschberg. (2004) Antigen delivery systems. Expert Review of Vaccines 3:4, 453-462
CrossRef172
Pedram Sendi, Rebecca Locher, Bruno Bucheli, Manuel Battegay. (2004) Intranasal Influenza Vaccine in a Working Population. Clinical Infectious Diseases 38:7, 974-980
CrossRef173
Couch, Robert B., . (2004) Nasal Vaccination, Escherichia coli Enterotoxin, and Bell's Palsy. New England Journal of Medicine 350:9, 860-861
Full Text
